Conference Proceedings
RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086
Sherene Loi, Peter Schmid, Javier Cortes, David W Cescon, Eric P Winer, Deborah Toppmeyer, Hope S Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette Tan, Chunsheng Zhang, Andrey Loboda, Andrew Albright, Razvan Cristescu, Maureen Lane, Anran Wang, Jared Lunceford, Gursel Aktan Show all
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Background: Response to anti-programmed death 1/programmed death ligand 1 (PD-L1) therapy is associated with tumor expression of PD-L1 and an 18-gene T-cell-inflamed gene expression profile (GEP) across several tumor types. The association and utility of the GEP, as calculated using baseline RNA-seq data as a predictor of pembrolizumab response, was evaluated in patients with triple-negative breast cancer (TNBC) enrolled in the KEYNOTE-086 trial (NCT02447003). Additionally, a 37-gene tissue -resident memory (TRM) T-cell signature was evaluated and compared with the GEP. Methods: In the phase II KEYNOTE-086 study, patients with previously treated, ..
View full abstract